IRF4 and gastric cancer: For instance, a large study which included 362 GC patients from Lima, Peru fond that IRF4 (OMIM #601900), ELMO1(OMIM #606420), CLIP4 (OMIM #605736) and MSC (OMIM #603628) promoter methylation coupled with a GDMI > 4 are useful molecular tools for GC risk stratification in endoscopic biopsies (Pirini et al., 2017).